Welcome to our dedicated page for InspireMD SEC filings (Ticker: NSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on InspireMD's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into InspireMD's regulatory disclosures and financial reporting.
InspireMD, Inc. amendment discloses that Nantahala Capital Management, LLC and its principals beneficially own 4,819,647 shares of common stock, representing 9.99% of the class as of March 31, 2026. The disclosed holdings include 1,443,163 shares that may be acquired within sixty days through the exercise of convertible securities.
The filing states that Nantahala holds these shares on behalf of funds and separately managed accounts and that Messrs. Wilmot B. Harkey and Daniel Mack are control persons with shared voting and dispositive power over the same block.
InspireMD, Inc. director Paul Stuka reported open-market purchases of the company’s common stock. He bought 10,000 shares on May 13, 2026 at $1.1575 per share and 5,000 shares on May 14, 2026 at $1.1500 per share, for a total of 15,000 shares.
After these direct purchases, he directly owned 647,871 shares. An additional 423,704 shares are held indirectly through Osiris Investment Partners, L.P.; the filing states no transaction occurred in those indirect holdings and that they are included for informational purposes, with beneficial ownership disclaimed except for any pecuniary interest.
InspireMD, Inc. ownership disclosure: Velan Capital Master Fund and related Velan entities report beneficial ownership of 2,347,779 shares of Common Stock, representing approximately 4.99% of the outstanding shares.
The filing states the shares outstanding were 46,801,561 as of March 18, 2026. The report also lists Warrants exercisable into 452,015 Series J, 452,014 Series K and 904,029 Pre-funded shares, each subject to 4.99% beneficial ownership limitations; certain warrant issuable amounts are excluded from the reported ownership due to those limits.
InspireMD, Inc. CEO and President Marvin Slosman reported an open-market purchase of 21,000 shares of Common Stock at $1.20 per share. Following this transaction, he directly owns 3,556,658 InspireMD shares, indicating a modest increase in his personal stake in the company.
InspireMD, Inc. director Paul Stuka reported open-market purchases of 75,626 shares of Common Stock. He bought 65,626 shares on May 8, 2026 at a weighted average price between $1.15 and $1.16, and 10,000 shares on May 11, 2026 at a weighted average price between $1.17 and $1.20.
Following these purchases, he directly beneficially owned 632,871 shares and indirectly, through Osiris Investment Partners, L.P., beneficially owned 423,704 shares. The amendment also corrects earlier reports by confirming certain shares were held directly rather than indirectly and states that these corrections did not change his pecuniary interest. It further clarifies that the transactions were not effected under a Rule 10b5-1(c) trading plan and that the Osiris-held shares are included here for informational purposes only.
InspireMD, Inc. director Paul Stuka reported open-market purchases of the company’s common stock. On May 8, 2026, he bought 65,626 shares at a weighted average price of $1.16 per share, followed by another 10,000 shares on May 11, 2026 at a weighted average price of $1.19 per share.
After these transactions, Stuka directly beneficially owned 632,871 shares of InspireMD common stock. Footnotes state that, immediately before these trades, he directly owned 557,245 shares and indirectly, through Osiris Investment Partners, L.P., beneficially owned 423,704 shares. The Osiris-held shares are reported for informational purposes, with Stuka disclaiming beneficial ownership except to the extent of his pecuniary interest.
InspireMD, Inc. director Ward Scott R. reported open-market purchases of company common stock. He bought 15,995 shares on May 6 and 73,255 shares on May 7 at a weighted average price of $1.15 per share, with individual trade prices ranging from $1.13 to $1.15. Following these transactions, he directly holds 237,096 shares of InspireMD common stock.
InspireMD, Inc. director Paul Stuka increased his stake through open-market purchases of Common Stock. On May 7, 2026, he bought 6,378 shares at $1.15 per share, and on May 6, 2026 he bought 1,517 shares at $1.12 per share. After these transactions, he directly holds 531,599 shares of InspireMD common stock. A footnote explains that the May 7 price reflects a weighted average for multiple trades executed between $1.14 and $1.15 per share.
InspireMD, Inc. director Gary S. Roubin made an open-market purchase of 90,000 shares of Common Stock. He bought the shares at a weighted average price of $1.18 per share, through multiple trades between $1.15 and $1.20. Following this transaction, he directly owns 834,478 shares, increasing his personal stake in the company.
InspireMD reported sharply higher Q1 2026 revenue but deeper losses and serious liquidity risk. Revenue rose to $3.4 million, up 122% from $1.5 million, driven mainly by the U.S. launch of CGuard Prime and growth in international sales.
Gross margin improved slightly to 20.2%, but operating expenses climbed to $14.7 million as the company expanded U.S. R&D and commercialization. Net loss widened to $13.7 million, and operating cash outflow reached $12.3 million. Cash and marketable securities totaled $41.6 million at quarter end.
The company disclosed a voluntary U.S. recall of its CGuard Prime 135 cm delivery system, with estimated reserves of about $700,000 for customer returns and $650,000 for inventory impairment and remediation. Management states there is substantial doubt about its ability to continue as a going concern without additional capital, and highlights ongoing geopolitical risks tied to its Israeli manufacturing base.